Clinical Program Updates News Today

Following merger with Adaptive Phage Therapeutics in March, combined company reports funding sufficient to support important data readouts for lead clinical programs in 2025 Company will host a...

Following merger with Adaptive Phage Therapeutics in March, combined company reports funding sufficient to support important data readouts for lead c

Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome Expected in Second Quarter 2024 Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in Geographic Atrophy Expected in mid-2024, a Global...

15.02.2024 - First-in-class IV SMARCA2 degrader and potentially best-in-class CDK9 inhibitor on track to generate potential proof-of-concept data in 2024 Highly selective oral SMARCA2 degrader PRT7732 IND expected to be filed in first half and enter Phase 1 ...

Updated Interim Results for the Six Months Ended 30 June 2023 NEW YORK, December 29, 2023 - Tiziana Life Sciences, Ltd. , a biotechnology company developing breakthrough...

Tiziana Life Sciences Ltd Updated Interim Results for the Six Months Ended 30 June 2023 NEW YORK, December 29, 2023 -...

13.11.2023 - Company Prioritizes Greatest Near-term Value-Driving Programs: ANX005 for Guillain-Barré Syndrome (GBS), ANX007 for Geographic Atrophy (GA) and First-in-Kind Complement Small Molecule, ANX1502 ANX005 Phase 3 Pivotal Data in GBS On Track for ...

New pipeline program builds on academic studies of durable, drug-free remissions in patients with autoimmune disease after CD19-targeted cell therapy NKX019, an allogeneic CAR NK cell therapy targeting CD19+ B

RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne that includes an optimized transgene for a novel microdystrophin, continues to be...

-- Robust enrollment in Phase 2 portion of randomized Phase 2/3 study of GRANITE to date; 71 of 80 patients enrolled as of May 10, 2023 -- -- Gritstone prioritizing GRANITE; expanding Phase 2 from... | May 11, 2023